Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
Stock Information for Hepion Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.